Advancis Gets Second Chance On Pulsatile Amoxicillin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans to resubmit application with additional information in March.
You may also be interested in...
MiddleBrook Aims To Address $600 Million Strep Market With Moxatag
Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.
MiddleBrook Aims To Address $600 Million Strep Market With Moxatag
Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.
Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA
Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.